Canaan’s Post

💎Today we announced another major milestone for Dewpoint Therapeutics – the nomination of DPTX3186 as the first condensate modulating (#cmod) development candidate, for the treatment of Wnt-driven cancers. 💧C-mods are a novel class of therapeutic agents designed to modify disease by targeting biomolecular #condensates. 🔬DPTX3186 c-mod inhibits the function of a historically ‘undruggable’ target – beta catenin.  🧬In preclinical models of Wnt-driven cancers, DPTX3186 demonstrates significant tumor growth inhibition, stasis and regression.  Read more about the program here: https://lnkd.in/g4Yi22Jz Learn more about the novel mechanism of action of the beta catenin-targeting c-mods here: https://lnkd.in/gj8jUw5r  

Another milestone - small molecule screening is delivering results.

Peptide-Based Cancer Therapeutics Market Projected to Reach $17.18 Billion by 2027 Polaris Market Research & Consulting, Inc. #peptidebasedtherapeutics #cancertherapy #oncology #biopharma #cancerresearch #drugdevelopment #targetedtherapy #healthcareinnovation #peptidetherapy #pharmaceuticals

Adcentrx begins patient dosing in phase 1a/b study of ADRX-0405, a potential first-in-class ADC targeting STEAP1 to treat advanced solid tumours

📢 Exciting News Alert! Our latest breakthrough in cancer treatment has been published in Advanced Science! Led by Dr. Allen Yueh-Hsiang Yu, our Senior Manager of Preclinical Development of Oncology Drugs, our research introduces "TE-1146," an innovative Antibody-Drug Conjugate (#ADC) for multiple #myeloma treatment. This groundbreaking study showcases our proprietary ADC platform, composed of innovative Multi-Arm Linker designs and enzyme-free, site-specific, bioconjugation method, along with the pioneering use of lenalidomide as an ADC payload. TE-1146 demonstrates superior efficacy compared to standard treatments, offering promising solutions for patients battling multiple myeloma. Dive into the full publication to explore our journey in advancing cancer therapeutics!  https://lnkd.in/g9_acZBk #CancerResearch #Innovation #ADC #AdvancedScience

Iambic Therapeutics has advanced its first pipeline candidate into the clinic, an AI-designed treatment for human epidermal growth factor receptor 2 (HER2)-driven cancers that moved from discovery to a first-in-human study in under two years—less than one-third of the average six-year conventional early drug development timeframe. IAM1363 is a selective and brain-penetrant small molecule inhibitor of HER2 signaling for solid tumors. Iambic has dosed its first patient in a Phase I/Ib trial (NCT06253871) designed to evaluate the tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of IAM1363, both as monotherapy and in combination with trastuzumab in patients with advanced HER2 cancers. #HER2cancers #Oncology #Clinicaltrials #Innovation #AI #Artificialintelligence #AIdesigndrug #CEOs #Drughunting

Lantern Pharma Inc. (Nasdaq: LTRN) announced #AI powered #collaboration with OregonTherapeutics to optimize development of first-in-class drug candidate XCE853 – a potent inhibitor of cancer metabolism. The collaboration is leveraging RADR®’s #AI-based capabilities, including 200+ #machinelearning (ML) algorithms and foundational models for #oncology drug development to uncover biomarkers and molecular correlates of efficacy and define potential combination regimens to sharpen XCE853’s drug development strategy. Learn more about the collaboration here: https://lnkd.in/g_DXWHBZ

📰 Extra! Extra! Read all about it! 📰   In the latest article for Drug Target Review, our CEO Roman Thomas describes how DISCO Pharmaceuticals GmbH - The #Surfaceome Company, uses its disruptive technology to comprehensively map the surface proteins of cancer cells in search of new targets for novel cancer drugs.    To learn more about DISCO and how its cutting-edge technology could change the future of cancer-targeted therapies of all modalities, including #ADCs, #Tcell engagers, #CARTcells and #radiopharmaceuticals, read the full article here 👉 https://bit.ly/3W1QK0x

🚀 The Antibody-Drug Conjugates (ADC) market is poised for significant growth, driven by increasing demand for targeted cancer therapies. With advancements in technology and expanding pipelines, ADCs are revolutionizing oncology treatments by offering enhanced precision in targeting tumor cells, while minimizing damage to healthy tissues. #ADCmarket #antibodydrugconjugates #globaldata

LucidQuest Strategic Insights (lqventures.com) >>> Gene&Cell Therapy >> At Third Arc Bio, former J&J leaders raise $165M to test oncology, autoimmune biologics: After more than a decade steering Johnson & Johnson’s oncology drug R&D, Peter Lebowitz is ready for his next challenge: shepherding the “third arc” of biologics development. “The first one was single targets for the antibody and binding to a cytokine or cell surface receptor. The second one was engineering those antibodies a little differently, either modifying the Fc, putting on a toxin, putting on a radioconjugate,” Lebowitz said in an interview with Endpoints News. “The third is multispecific antibodies that actually bind to different cell types and bring in new biology.” In that vein, Lebowitz is now running a new biologics startup named Third Arc Bio founded by another former J&J leader: Sanjaya Singh. The company raised a $165 million Series A that will be used to move three experimental multispecific antibodies for solid tumors and inflammatory and immunology (I&I) diseases into the clinic. The unveiling was announced the same morning as the launch of another biologics-focused oncology and immunology biotech. Earlier on Tuesday, Flagship Pioneering took the wraps off a $50 million commitment to its Abiologics offshoot. Founded in 2022, Third Arc Bio is working on multispecific antibodies for solid tumors, inflammatory bowel disease, rheumatoid arthritis, lupus and so-called Th2 diseases, which entail a broad scope of inflammatory conditions, according to Lebowitz. “At J&J, I saw all the platforms. We had them all. I specifically wanted to work on [multispecific antibodies] because this is the area where there is the largest opportunity to meet unmet need,” Lebowitz said. “There’s a lot of interest in ADCs now, and ADCs are very important. But this is the area that is right in the right spot of the breaking point where it goes over the edge and actually is transformational for solid tumors.” He “retired” from J&J on Jan. 1 and joined Third Arc as CEO on Jan. 2. In his role as head of oncology R&D, Lebowitz solidified the pharma giant’s work in CAR-T cell therapies with partner Legend Biotech and oversaw a series of wins in multiple myeloma, among other areas of oncology. While at J&J, he worked with Third Arc founder and chief scientific officer Singh, in addition to chief operating officer Joe Erhardt. The trio has “collectively delivered 19 new medicines,” Lebowitz said. Debi Watson, another longtime J&J leader, is the startup’s chief business officer. ‘Atypical Series A’ Oncology remains a big area of investment for biotech venture capitalists, and I&I continues to drum up large financings and M&A deals. With a pipeline spanning both areas, Third Arc was able to attract the 58th private biotech megaround of 2024, according to Endpoints’ ongoing tally.… #lucidquest #genetherapy #celltherapy